Fast diagnostic tests (RDTs) are becoming increasingly a paradigm for both clinical diagnosis of malaria infections as well as for calculating community parasite prevalence in household malaria indicator surveys in malaria-endemic nations. The antigens detected by RDTs are known to persist into the bl dstream after treatment with anti-malarials, but reports on the period of perseverance ( plus the impact it has on RDT positivity) of these antigens post-treatment are adjustable.
In this review, posted studies on the determination of positivity of RDTs post-treatment are collated, and a bespoke bayesian survival model is fit to calculate the number of times RDTs remain g d after treatment.
50 % of RDTs that detect the antigen histidine-rich protein II (HRP2) remain positive 15 (5вЂ“32) days post-treatment, 13 times much longer than RDTs that detect the antigen Plasmodium lactate dehydrogenase, and that 5% of HRP2 RDTs remain g d 36 (21вЂ“61) times after therapy. The period of persistent positivity for combination RDTs that detect both antigens falls between that for HRP2- or pLDH-only RDTs, with 1 / 2 of RDTs staying g d at 7 (2вЂ“20) days post-treatment. This research shows that children display persistent RDT positivity for longer after treatment than adults, and that persistent positivity is more common whenever an individual is treated with artemisinin combination treatment than whenever treated along with other anti-malarials.
RDTs remain positive for a extremely adjustable amount of time after treatment with anti-malarials, therefore the duration of positivity is extremely dependent on the sort of RDT useful for diagnosis. Also, age and treatment both effect the extent of determination of RDT positivity. The outcomes provided here suggest that care should be taken when utilizing RDT-derived diagnostic results from cross-sectional information where people have had a present history of anti-malarial therapy. (more…)